Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

It can take a long time to create a new vaccine and at the same time, there have been many evolutions and new strains of the ...

Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million Novavax headquarters to remain in ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Novavax is pushing ahead with plans to slim down with a deal to offload one its locations in Maryland and surrounding property, which is expected to net $60 million in cash for the vaccine maker.

In the latest close session, Novavax (NVAX) was down 4.02% at $9.08. This move lagged the S&P 500's daily gain of 0.37%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 0.71%.